翰森制药(03692)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03692 翰森制药

休市中 05-16 16:08:20

23.450

+0.850

+3.76%

最高23.800	最低22.650	成交量1,237万
今开22.800	昨收22.600	日振幅5.09%
总市值1,395亿	流通市值1,395亿	总股本59.47亿
成交额2.85亿	换手率0.21%	流通股本59.47亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03692","market":"HK","secType":"STK","nameCN":"翰森制药","latestPrice":23.45,"timestamp":1747382900031,"preClose":22.6,"halted":0,"volume":12371582,"delay":0,"floatShares":5947000000,"shares":5947000000,"eps":0.7987671120678879,"marketStatus":"休市中","change":0.85,"latestTime":"05-16 16:08:20","open":22.8,"high":23.8,"low":22.65,"amount":285374563,"amplitude":0.050885,"askPrice":23.45,"askSize":12000,"bidPrice":23.4,"bidSize":26000,"shortable":3,"etf":0,"ttmEps":0.7961938551681567,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1747618200000},"marketStatusCode":7,"adr":0,"listingDate":1560441600000,"exchange":"SEHK","adjPreClose":22.6,"dividendRate":0.014478,"openAndCloseTimeList":[[1747359000000,1747368000000],[1747371600000,1747382400000]],"volumeRatio":0.877385,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03692","defaultTab":"news","newsList":[{"id":"2535411361","title":"翰森制药05月16日获主力加仓685.6万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2535411361","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535411361?lang=zh_cn&edition=full","pubTime":"2025-05-16 16:15","pubTimestamp":1747383321,"startTime":"0","endTime":"0","summary":"05月16日, 翰森制药股价涨3.76%，报收23.45元，成交金额2.9亿元，换手率0.21%，振幅5.09%，量比0.87。翰森制药今日主力资金净流入685.6万元，上一交易日主力净流入528.2万元。该股近5个交易日下跌1.90%，主力资金累计净流入9147.6万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流入1.5亿元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250516172617a6e17688&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250516172617a6e17688&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1589","BK1191","03692","BK1583"],"gpt_icon":0},{"id":"2534299619","title":"翰森制药(03692)下跌7.38%，报21.95元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2534299619","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534299619?lang=zh_cn&edition=full","pubTime":"2025-05-12 13:52","pubTimestamp":1747029124,"startTime":"0","endTime":"0","summary":"5月12日，翰森制药盘中下跌7.38%，截至13:52，报21.95元/股，成交4.32亿元。翰森制药集团有限公司是一家中国领先的创新驱动型制药企业，主要关注抗肿瘤、抗感染、中枢神经系统类疾病、代谢疾病及自身免疫性疾病等领域。2023年总营收突破百亿规模，其中创新产品营收占比67.9%。截至2024年年报，翰森制药营业总收入122.61亿元、净利润43.72亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/05/12135250301796.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1583","03692","BK1191","BK1589"],"gpt_icon":0},{"id":"2534506452","title":"翰森制药盘中异动 早盘快速下跌5.91%报22.300港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2534506452","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534506452?lang=zh_cn&edition=full","pubTime":"2025-05-12 09:30","pubTimestamp":1747013406,"startTime":"0","endTime":"0","summary":"2025年05月12日早盘09时30分，翰森制药股票出现异动，股价急速下跌5.91%。截至发稿，该股报22.300港元/股，成交量19.9045万股，换手率0.00%，振幅4.22%。资金方面，该股资金流入195.43万港元，流出73.24万港元。翰森制药股票所在的药品行业中，整体跌幅为0.47%。其相关个股中，凯莱英、丽珠医药、华润医药涨幅较大，振幅较大的相关个股有翰森制药、石药集团、信达生物，振幅分别为4.22%、0.87%、0.76%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250512093006a6db88bb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250512093006a6db88bb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03692","BK1191","BK1583","BK1589"],"gpt_icon":0},{"id":"2534177653","title":"翰森制药(03692)：阿美乐®(甲磺酸阿美替尼片)第四项适应症获国家药品监督管理局签发药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2534177653","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534177653?lang=zh_cn&edition=full","pubTime":"2025-05-09 17:55","pubTimestamp":1746784500,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰森制药(03692)发布公告，本集团创新药阿美乐®(甲磺酸阿美替尼片)获中国国家药品监督管理局(NMPA)签发的药品注册证书，批准增加“用于II-IIIB期具有表皮生长因子受体(“EGFR”)外显子19缺失或外显子21(L858R)置换突变的成人非小细胞肺癌“NSCLC”)患者的治疗，患者须既往接受过手术切除治疗，并由医生决定接受或不接受辅助化疗”适应症。此为阿美乐®获批的第四项适应症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1291429.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03692","BK1191","BK1583","BK1589"],"gpt_icon":0},{"id":"2534999483","title":"翰森制药：阿美乐®(甲磺酸阿美替尼片)第四项适应症获国家药品监督管理局签发药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2534999483","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534999483?lang=zh_cn&edition=full","pubTime":"2025-05-09 17:53","pubTimestamp":1746784413,"startTime":"0","endTime":"0","summary":"格隆汇5月9日丨翰森制药发布公告，集团创新药阿美乐获中国国家药品监督管理局签发的药品注册证书，批准增加“用于II-IIIB期具有表皮生长因子受体外显子19缺失或外显子21置换突变的成人非小细胞肺癌“NSCLC”）患者的治疗，患者须既往接受过手术切除治疗，并由医生决定接受或不接受辅助化疗”适应症。此为阿美乐获批的第四项适应症。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050917533394f19c65&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050917533394f19c65&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03692","BK1583","BK1589","BK1191"],"gpt_icon":0},{"id":"2534483990","title":"翰森制药05月09日获主力加仓238.9万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2534483990","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534483990?lang=zh_cn&edition=full","pubTime":"2025-05-09 16:15","pubTimestamp":1746778518,"startTime":"0","endTime":"0","summary":"05月09日, 翰森制药股价涨0.21%，报收23.70元，成交金额1.9亿元，换手率0.13%，振幅3.59%，量比1.00。翰森制药今日主力资金净流入238.9万元，连续3日净流入，上一交易日主力净流入286.7万元。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为53.33%，平均涨幅为1.84%。该股近5个交易日下跌0.83%，主力资金累计净流入150.6万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流入1.5亿元，其中净流入天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509174655a6d8e686&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509174655a6d8e686&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1589","03692","BK1191","BK1583"],"gpt_icon":0},{"id":"2534176614","title":"第 4 项适应症！翰森制药“阿美替尼”获批用于 NSCLC 辅助治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2534176614","media":"Insight数据库","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534176614?lang=zh_cn&edition=full","pubTime":"2025-05-09 15:35","pubTimestamp":1746776116,"startTime":"0","endTime":"0","summary":"5 月 9 日，NMPA 官网显示，翰森制药“甲磺酸阿美替尼片”（阿美乐）获批一项新适应症，用于具有表皮生长因素受体外显子 19 缺失或外显子 21置换突变阳性的非小细胞肺癌成人患者肿瘤切除术后的辅助治疗。这是一项随机、对照、双盲、多中心 III 期临床研究，旨在评估甲磺酸阿美替尼对比安慰剂用于表皮生长因子受体敏感突变阳性 II-IIIB 期 NSCLC 辅助治疗的有效性和安全性。研究共纳入 214 名中国患者，随机分配接受阿美替尼和安慰剂治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509170740a477e9bd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509170740a477e9bd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","03692","BK1589","BK1191"],"gpt_icon":0},{"id":"2534973124","title":"【券商聚焦】兴业证券上调翰森制药(03692)至“买入”评级 指其核心商业化创新药品种保持快速增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2534973124","media":"金吾财讯","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534973124?lang=zh_cn&edition=full","pubTime":"2025-05-09 15:32","pubTimestamp":1746775974,"startTime":"0","endTime":"0","summary":"该行续指，公司创新药收入占比高，驱动业绩保持快速增长，自主研发以及BD双轮驱动，早期管线布局丰富，同时积极进行国际化布局，打开海外市场想象空间。对应2025年5月2日收盘价，PE分别为30.77x、27.16x、23.83x，上调至“买入”评级。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/NWI3NDNkNGUxZmM1MTMzOTE0MzEwMTk=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NWI3NDNkNGUxZmM1MTMzOTE0MzEwMTk=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1958413","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692","601377","159992","06978"],"gpt_icon":0},{"id":"2533977461","title":"中证港股通生物科技主题指数报1198.91点，前十大权重包含翰森制药等","url":"https://stock-news.laohu8.com/highlight/detail?id=2533977461","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533977461?lang=zh_cn&edition=full","pubTime":"2025-05-08 17:12","pubTimestamp":1746695566,"startTime":"0","endTime":"0","summary":"数据统计显示，中证港股通生物科技主题指数近一个月上涨19.39%，近三个月上涨19.52%，年至今上涨26.95%。从中证港股通生物科技主题指数持仓的市场板块来看，香港证券交易所占比100.00%。从中证港股通生物科技主题指数持仓样本的行业来看，生物药品占比51.50%、化学药占比25.70%、制药与生物科技服务占比19.44%、医疗器械占比3.36%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050817153294f04778&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050817153294f04778&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1589","BK1583","HSTECH","03692","HSCEI"],"gpt_icon":1},{"id":"2533055625","title":"翰森制药盘中异动 股价大跌3.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2533055625","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533055625?lang=zh_cn&edition=full","pubTime":"2025-05-07 14:02","pubTimestamp":1746597732,"startTime":"0","endTime":"0","summary":"2025年05月07日下午盘14时02分，翰森制药股票出现波动，股价急速下跌3.07%。翰森制药股票所在的药品行业中，整体跌幅为0.53%。2024年，翰森制药的创新药与合作产品销售收入为94.77亿元，占总收入比例提升至77.3%，成为业绩增长核心动力。2024年，翰森制药研发开支为27.02亿元，同比增长约28.8%，目前正在进行的创新药临床试验超60项，分属40个候选创新药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507140212a6d5eb55&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507140212a6d5eb55&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1589","03692","BK1191"],"gpt_icon":0},{"id":"2533630673","title":"翰森制药口服 GLP-1R 激动剂启动肥胖 II 期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2533630673","media":"Insight数据库","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533630673?lang=zh_cn&edition=full","pubTime":"2025-05-07 11:20","pubTimestamp":1746588036,"startTime":"0","endTime":"0","summary":"5 月 6 日，翰森制药在药物临床试验登记与信息公示平台上登记了一项在超重和肥胖受试者中评估每天一次口服 HS-10501/HS-10501-2 的有效性和安全性的多中心、随机、双盲、安慰剂对照的 Ⅱ 期临床研究。该研究计划纳入 540 名受试者，随机分组接受HS-10501、HS-10501-2、安慰剂治疗，每日一次。HS-10501 用药时程为 36 周，HS-10501-2 用药时程为 26 周。主要终点是给药 26 周后，体重较基线下降的百分比。HS-10501-2 剂型为缓释片。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507155715a47506cc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507155715a47506cc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1589","BK1191","03692"],"gpt_icon":0},{"id":"2533509697","title":"翰森制药2024年溢利增长33% 创新药方面为核心支柱","url":"https://stock-news.laohu8.com/highlight/detail?id=2533509697","media":"GPLP犀牛财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533509697?lang=zh_cn&edition=full","pubTime":"2025-05-06 15:58","pubTimestamp":1746518308,"startTime":"0","endTime":"0","summary":"4月28日，翰森制药发布年报，2024年录得收入122.61亿元，同比增长约21.3%；录得年内溢利约43.72亿元，同比增长约33.4%；基本每股盈利为0.74元/股，业绩增长主要得益于创新药及合作产品收入增加。2024年，翰森制药的创新药与合作产品销售收入为94.77亿元，占总收入比例提升至77.3%，成为业绩增长核心动力。2024年，翰森制药研发开支为27.02亿元，同比增长约28.8%，目前正在进行的创新药临床试验超60项，分属40个候选创新药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250506155847975064cc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250506155847975064cc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","BK1589","BK1583","03692","BK1191","BK1574","BK1161"],"gpt_icon":0},{"id":"2533515393","title":"翰森制药盘中异动 股价大涨3.07%报25.150港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2533515393","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533515393?lang=zh_cn&edition=full","pubTime":"2025-05-06 10:11","pubTimestamp":1746497507,"startTime":"0","endTime":"0","summary":"2025年05月06日早盘10时11分，翰森制药股票出现异动，股价急速上涨3.07%。截至发稿，该股报25.150港元/股，成交量397.755万股，换手率0.07%，振幅4.71%。翰森制药股票所在的药品行业中，整体涨幅为0.07%。消息层面，截至10时11分，《翰森制药：2024年净利润43.72亿元 同比增长33.39% 拟每股派息0.1353港元》资讯为影响翰森制药的重要信息。数据显示，2024年公司加权平均净资产收益率为15.89%，较上年同期上升2.45个百分点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250506101148a473613e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250506101148a473613e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1191","BK1589","03692"],"gpt_icon":0},{"id":"2532797078","title":"翰森制药：B7-H4靶向抗体-药物偶联物HS-20089获国药监局纳入突破性治疗药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2532797078","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532797078?lang=zh_cn&edition=full","pubTime":"2025-05-01 18:57","pubTimestamp":1746097020,"startTime":"0","endTime":"0","summary":"翰森制药发布公告，于2025年5月1日，集团自研B7-H4靶向抗体-...翰森制药发布公告，于2025年5月1日，集团自研B7-H4靶向抗体-药物偶联物注射用HS-20089获中国国家药品监督管理局批准纳入突破性治疗药物，拟定适应症为用于铂耐药复发上皮性巢癌、输管癌或原发性腹膜癌患者。据悉，HS-20089是一种B7-H4靶向ADC，其有效载荷为拓扑异构酶抑制剂，正于中国开展用于治疗巢癌以及其他妇科肿瘤的多项临床研究，其中最高研究阶段为临床III期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250501185942a46ed24e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250501185942a46ed24e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1589","03692","BK1583","BK1191"],"gpt_icon":0},{"id":"2532200170","title":"翰森制药(03692)：B7-H4靶向抗体-药物偶联物HS-20089获国药监局纳入突破性治疗药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2532200170","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532200170?lang=zh_cn&edition=full","pubTime":"2025-05-01 18:49","pubTimestamp":1746096552,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰森制药 发布公告，于2025年5月1日，集团自研B7-H4靶向抗体-药物偶联物注射用HS-20089获中国国家药品监督管理局批准纳入突破性治疗药物，拟定适应症为用于铂耐药复发上皮性卵巢癌、输卵管癌或原发性腹膜癌患者。据悉，HS-20089是一种B7-H4靶向ADC，其有效载荷为拓扑异构酶抑制剂，正于中国开展用于治疗卵巢癌以及其他妇科肿瘤的多项临床研究，其中最高研究阶段为临床III期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1288808.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"翰森制药(03692)：B7-H4靶向抗体-药物偶联物HS-20089获国药监局纳入突破性治疗药物","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1589","BK1583","BK1191","03692"],"gpt_icon":0},{"id":"2531085284","title":"翰森制药04月30日主力净流入690.9万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2531085284","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531085284?lang=zh_cn&edition=full","pubTime":"2025-04-30 16:15","pubTimestamp":1746000927,"startTime":"0","endTime":"0","summary":"04月30日, 翰森制药股价涨2.34%，报收24.10元，成交金额2.1亿元，换手率0.15%，振幅3.18%，量比0.95。翰森制药今日主力资金净流入690.9万元，上一交易日主力净流出1854.5万元。该股近5个交易日上涨1.89%，主力资金累计净流出2734.6万元；近20日主力资金累计净流入2.9亿元，其中净流入天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430170603a6ce9946&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430170603a6ce9946&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","03692","BK1191","BK1589"],"gpt_icon":0},{"id":"2531729470","title":"翰森制药盘中异动 早盘股价大涨3.18%报24.300港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531729470","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531729470?lang=zh_cn&edition=full","pubTime":"2025-04-30 11:09","pubTimestamp":1745982569,"startTime":"0","endTime":"0","summary":"2025年04月30日早盘11时09分，翰森制药股票出现波动，股价大幅上涨3.18%。截至发稿，该股报24.300港元/股，成交量226.254万股，换手率0.04%，振幅2.76%。翰森制药股票所在的药品行业中，整体涨幅为0.14%。其相关个股中，励晶太平洋、翰森制药、远大医药涨幅较大，振幅较大的相关个股有励晶太平洋、泰凌医药、精优药业，振幅分别为23.47%、12.64%、7.84%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025043011092994e8598a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025043011092994e8598a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03692","BK1583","BK1191","BK1589"],"gpt_icon":0},{"id":"2531123252","title":"翰森制药盘中异动 快速拉升3.01%报23.950港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531123252","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531123252?lang=zh_cn&edition=full","pubTime":"2025-04-29 10:13","pubTimestamp":1745892804,"startTime":"0","endTime":"0","summary":"2025年04月29日早盘10时13分，翰森制药股票出现波动，股价大幅上涨3.01%。截至发稿，该股报23.950港元/股，成交量104.8万股，换手率0.02%，振幅2.58%。翰森制药股票所在的药品行业中，整体涨幅为0.27%。该信息摘要如下：美银证券发布研报称，翰森制药旗下阿美替尼片在今年首两个月销售额激增76.9%，带动公司销售表现强劲，因此上调2025、2026及2027年收入预测各1.9%、2.5%及2.7%，目标价由24.8港元升至29港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042910132594e6bc0d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042910132594e6bc0d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1589","03692","BK1191"],"gpt_icon":0},{"id":"2531218947","title":"翰森制药授出856.1万份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2531218947","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531218947?lang=zh_cn&edition=full","pubTime":"2025-04-29 09:04","pubTimestamp":1745888640,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　翰森制药（03692）发布公告，于2025年4月28日，根据公司于2019年5月27日采纳的首次公开发售后受限制股份单位计划，向776名受限制股份单位承授人授出合共代表856.1万股股份的受限制股份单位，但须经承授人接纳作实。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-04-29/doc-ineuuwaa1210834.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1583","BK1589","03692","BK1191"],"gpt_icon":0},{"id":"2530100283","title":"翰森制药(03692)授出856.1万份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2530100283","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530100283?lang=zh_cn&edition=full","pubTime":"2025-04-28 21:19","pubTimestamp":1745846341,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰森制药(03692)发布公告，于2025年4月28日，根据公司于2019年5月27日采纳的首次公开发售后受限制股份单位计划，向776名受限制股份单位承授人授出合共代表856.1万股股份的受限制股份单位，但须经承授人接纳作实。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1286748.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1583","03692","BK1589"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0105},{"period":"1month","weight":0.0732},{"period":"3month","weight":0.3385},{"period":"6month","weight":0.373},{"period":"1year","weight":0.3159},{"period":"ytd","weight":0.3571}],"compareEarnings":[{"period":"1week","weight":0.0209},{"period":"1month","weight":0.1087},{"period":"3month","weight":0.032},{"period":"6month","weight":0.2017},{"period":"1year","weight":0.2048},{"period":"ytd","weight":0.1638}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"翰森制药集团有限公司是一家主要从事一系列药品的研发、生产及销售的投资控股公司。该公司的创新药产品包括阿美乐、豪森昕福、迈灵达、孚来美、恒沐、昕越、圣罗莱等产品。该公司的创新药产品主要应用于抗肿瘤、抗感染、中枢神经系统（CNS）疾病、代谢及其他治疗领域。该公司主要在国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":-0.014632},{"month":2,"riseRate":0.5,"avgChangeRate":0.000739},{"month":3,"riseRate":0.333333,"avgChangeRate":0.024787},{"month":4,"riseRate":0.5,"avgChangeRate":0.032026},{"month":5,"riseRate":0.5,"avgChangeRate":0.00274},{"month":6,"riseRate":0.6,"avgChangeRate":0.03658},{"month":7,"riseRate":0.5,"avgChangeRate":-0.032646},{"month":8,"riseRate":0.666667,"avgChangeRate":0.018947},{"month":9,"riseRate":0.5,"avgChangeRate":-0.03981},{"month":10,"riseRate":0.166667,"avgChangeRate":0.003801},{"month":11,"riseRate":0.666667,"avgChangeRate":0.052626},{"month":12,"riseRate":0.666667,"avgChangeRate":0.036825}],"exchange":"SEHK","name":"翰森制药","nameEN":"HANSOH PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.5","shortVersion":"4.33.5","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"翰森制药(03692)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供翰森制药(03692)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"翰森制药,03692,翰森制药股票,翰森制药股票老虎,翰森制药股票老虎国际,翰森制药行情,翰森制药股票行情,翰森制药股价,翰森制药股市,翰森制药股票价格,翰森制药股票交易,翰森制药股票购买,翰森制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"翰森制药(03692)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供翰森制药(03692)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}